2024 Australasian Ocular Melanoma Alliance (AOMA) Virtual Summit
Date: 15/06/2024 (AEST)
Register Here: https://www.masc.org.au/aoma-summit/
Provider: Melanoma and Skin Cancer Trials
Contact: Merrin Morrison, [E] hello@masc.org.au, [P] +61 3 9903 9022
Activity Outline
The 2024 Australasian Ocular Melanoma Alliance (AOMA) Virtual Summit will bring together healthcare professionals, researchers, and consumers in ocular melanoma to share the latest research and facilitate national and international collaborations for this rare, aggressive, and often devastating cancer.
This free virtual event will feature international and Australian ocular melanoma experts, along with consumers who will present on their experiences with ocular melanoma. The summit will cover the latest in clinical trials, ocular melanoma therapies, advances in ophthalmology, new Australian and international research, radiation oncology, and more.
Learning Objectives
- Understand about the latest drug development in the USA for uveal melanoma
- Understand how advocacy and support for ocular melanoma patients is being delivered in the USA
- Understand how an Australian and New Zealand uveal melanoma registry will contribute to international registries to identify predictive clinical features of uveal melanoma
- Understand how an AU & NZ uveal melanoma registry will contribute to international registries to document the natural history & collect real world data regarding clinical management of uveal melanoma
- Understand the challenges regional Australians with ocular melanoma face in accessing diagnosis, treatment, and ongoing care
- Know how this recently PBS listed drug for metastatic uveal melanoma works, and what patients need to know about accessing and being treated with this therapy
- Understand the role and targeting of GNAQ and GNA11 in uveal melanoma
- Understand the challenges New Zealand patients with metastatic ocular melanoma have in accessing Tebentafusp, and how one patient travels to Australia each week for an infusion of this drug
- Understand the pathology workflow for uveal melanoma, integrating diagnostic and molecular prognostic testing with innovative tumour banking
- Know the latest research in liquid biopsies for uveal melanoma, with specific focus on circulating tumour cells and circulating tumour DNA
- Understand the latest novel interventions to address fear of cancer recurrence in ocular melanoma survivors
- Understand the latest research from clinical trials for cell therapy for uveal melanoma
- Understand how ophthalmologists treat ocular melanoma patients, with a focus on the Western Australian approach
- Understand the role of an ocularist in wholistically working with ocular melanoma patients through their eye loss, the development of an artificial eye, and living with this prothesis
- Understand an ocular melanoma patients journey through diagnosis, enucleation (removal of the eye), and being fitted with an artificial eye
- Know how multidisciplinary teams, including ophthalmologists and medical physicists, work together to treat ocular melanoma patients
- Understand the role of stereotactic radiotherapy in treating uveal melanoma
- Know about uveal melanoma clinical trials and registries in the UK, and the role of Percutaneous Hepatic Perfusion in treating uveal melanoma
- Understand how a young woman refused to let her ocular melanoma diagnosis stop her from living a fulfilling life, including starting a family and raising awareness of this rare cancer
Max CPD hours awarded: 5.25
Session Information
| Name |
|---|
| Uveal melanoma registries: Seeking to collate, catalogue and curate |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Living with ocular melanoma in rural Australia |
| Clinical? |
|---|
| No |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Tebentafusp - what you need to know as a patient |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Targeting GNAQ and GNA11 in uveal melanoma |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Dealing with ocular melanoma as a Kiwi |
| Clinical? |
|---|
| No |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Navigating the latest in uveal melanoma testing: options, interpretation and access pathways |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| ctDNA as a biomarker in uveal melanoma |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Fear of cancer recurrence: Addressing the elephant in the room |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Cell therapy for uveal melanoma |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| How we work up uveal melanoma: an opthalmologist's perspective for patients |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Navigating the journey of eye loss and recovery |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Seeing the light! |
| Clinical? |
|---|
| No |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Delivering world class patient care |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Advances in radiation oncology and the NSW experience |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| FOCUS, and the end of the beginning for liver directed therapy in metastatic uveal melanoma |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.5 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.5 |
| Name |
|---|
| Consumer presentation: Fear is the thief of joy: moving on after diagnosis |
| Clinical? |
|---|
| No |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Moving towards a cure: A new chapter for patients with uveal melanoma |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.5 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.5 |
| Name |
|---|
| Why advocacy is important |
| Clinical? |
|---|
| No |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.5 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.5 |
| Name | Clinical? | Interactive? | Therapeutic? | CPD Hours |
|---|
| Uveal melanoma registries: Seeking to collate, catalogue and curate | Yes | Yes | No | 0.25 | 0.25 |
| Living with ocular melanoma in rural Australia | No | Yes | No | 0.25 | 0.25 |
| Tebentafusp - what you need to know as a patient | Yes | Yes | Yes | 0.25 | 0.25 |
| Targeting GNAQ and GNA11 in uveal melanoma | Yes | Yes | Yes | 0.25 | 0.25 |
| Dealing with ocular melanoma as a Kiwi | No | Yes | No | 0.25 | 0.25 |
| Navigating the latest in uveal melanoma testing: options, interpretation and access pathways | Yes | Yes | No | 0.25 | 0.25 |
| ctDNA as a biomarker in uveal melanoma | Yes | Yes | Yes | 0.25 | 0.25 |
| Fear of cancer recurrence: Addressing the elephant in the room | Yes | Yes | No | 0.25 | 0.25 |
| Cell therapy for uveal melanoma | Yes | Yes | Yes | 0.25 | 0.25 |
| How we work up uveal melanoma: an opthalmologist's perspective for patients | Yes | Yes | Yes | 0.25 | 0.25 |
| Navigating the journey of eye loss and recovery | Yes | Yes | No | 0.25 | 0.25 |
| Seeing the light! | No | Yes | No | 0.25 | 0.25 |
| Delivering world class patient care | Yes | Yes | Yes | 0.25 | 0.25 |
| Advances in radiation oncology and the NSW experience | Yes | Yes | Yes | 0.25 | 0.25 |
| FOCUS, and the end of the beginning for liver directed therapy in metastatic uveal melanoma | Yes | Yes | Yes | 0.5 | 0.5 |
| Consumer presentation: Fear is the thief of joy: moving on after diagnosis | No | Yes | No | 0.25 | 0.25 |
| Moving towards a cure: A new chapter for patients with uveal melanoma | Yes | Yes | Yes | 0.5 | 0.5 |
| Why advocacy is important | No | Yes | Yes | 0.5 | 0.5 |